

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁶ : A61B 5/0408, A61N 1/04</p>	<p>A1</p>	<p>(11) International Publication Number: WO 00/45698</p> <p>(43) International Publication Date: 10 August 2000 (10.08.00)</p>
<p>(21) International Application Number: PCT/US99/02620</p> <p>(22) International Filing Date: 8 February 1999 (08.02.99)</p> <p>(71) Applicant: AXELGAARD MANUFACTURING COMPANY, LTD. [US/US]; 1667 South Mission Road, Fallbrook, CA 92028 (US).</p> <p>(72) Inventors: HEARD, Steve; 2012 Rachelle Place, Escondido, CA 92025 (US). FOX, Adrian, S.; 2477 S. Summit Circle Glen, Escondido, CA 92026 (US). AXELGAARD, Jens; 811 Tumbleweed Lane, Fallbrook, CA 92028 (US).</p> <p>(74) Agent: HACKLER, Walter, A.; Suite B, 2372 S.E. Bristol, Newport Beach, CA 92660 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>
<p>(54) Title: MEDICAL ELECTRODE</p> <p>(57) Abstract</p> <p>An electrode providing electrical contact with a patient's skin includes a conductive member (11) adapted for connection to an external electrical apparatus, a non-liquid film (15) for electrically interfacing to the patient's skin, the non-liquid film being electrically, and mechanically connected to the conductive member. The non-liquid film includes an electrically conductive organic polymer plasticized with a polyhydric alcohol with said organic polymer being derived from a monomeric mixture comprising from about 15 pph to 30 pph acrylic acid, 0.5 pph to 30 pph N-vinyl pyrrolidine and 0.01 pph to 2 pph of a crosslinking agent. The monomeric mixture may further comprise from about 0.5 pph to 8 pph of a thickening agent selected from the group consisting of N-vinyl pyrrolidine/acrylic acid copolymers and N-vinyl pyrrolidine/vinyl acetate.</p> <div data-bbox="548 1222 1344 1537"> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

MEDICAL ELECTRODEFIELD OF THE INVENTION

5 The present invention provides a combination
electrode for use in medical applications, e.g., medical
applications requiring monitoring and stimulation, having
an electrical current conductor including a connector in
addition to a skin-interfacing film wherein this film may
10 have adhesive, plastic and hydrophilic properties such as
may reside in an electrically conductive, polymeric
composition.

BACKGROUND OF THE ART

15 Medical electrodes have, in the past, taken many
shapes and forms. Principally, they have been shaped
according to the use for which they are intended.
Electrodes used with monitoring apparatus, such as EKG
20 and EEG machines, commonly have small round contact
surfaces, whereas electrodes used with such stimulation
apparatus as pain control devices tend to be larger and
have rectangularly and other conveniently shaped contact
surfaces. Whether intended for monitoring or stimulation
25 use, a design objective for each electrode group has
been, and continues to be, good electrical signal
transmission between a patient's skin surface and the
electrical cables connected to a particular piece of
apparatus. With respect to stimulation and monitoring
30 electrodes, efficient signal transmission across the
epidermis conductor interface is desirable. Further, with
respect to stimulation electrodes, effective signal

transmission free of current concentration points or "hot spots" is also desirable.

Of the electrodes presently available, many offer
5 combination structures including a metallic or otherwise
conductive support member to which an electrical wire
from an associated apparatus may be attached.

Certain of the currently available electrodes,
10 including electrical stimulation electrodes are disclosed
in U.S. Patents 4,722,354; 4,736,752; 4,819,328;
5,038,796 and 5,450,845 to Axelgaard et al which are
hereby incorporated by reference to show various
electrode designs including but not limited to medical
15 electrode shapes, structures, materials and methods for
connecting said medical electrodes to the appropriate
electrical apparatus.

In many instances, the medical electrodes of the
20 prior art need the addition of generous amounts of an
electrode paste or gel applied directly to the conductive
support member to enhance conductivity across the
skin-electrode interface to the point where acceptable
operating conditions are achieved.

25

Other prior art electrodes teach the incorporation
of an open cellular skin interface pad secured to a
conductive support member. This pad, as shown in U.S.
Patent No. 3,817,252, is often sponge material which
30 functions to hold an amount of electrolyte solution in
order to enhance conductivity across the skin-pad
interface. Such an interface pad can be, alternately,
saturated with electrode pastes or gels of the type that

do not run or evaporate as readily as electrolyte solutions.

The prior art electrodes that require an electrode
5 paste or gel or electrolyte solution provide a structure
which does not always maintain constant, efficient and
effective electrical transmission for long periods of
time without the need for additional electrode paste, gel
or solution. Moreover, there is a tendency while using
10 these electrodes, for the electrode gel to separate
and/or to flow to a nonuniform thickness. Under these
conditions, sections of the conductive support member
could be exposed to the skin and local hot spots can
result which can cause discomfort if not severe enough to
15 cause burns to the patient's skin. Therefore, medical
electrodes wherein the adhesive, itself, provides the
conductive interface between the skin and the electrical
connector are very desirable. An electrode of this type
is disclosed in U.S. Patent 4,066,078 to Berg. In this
20 patent, the polymer itself acts as the adhesive and,
through the quaternary groups attached to the polymer
backbone, provides a conductive interface.

Nevertheless, others have continued to formulate
25 adhesive materials that effectively adhere to the skin
and the materials that can be utilized in fabricating a
medical electrode and also provide adequate conductivity.
See, for example, U.S. Patent Nos. 4,830,776; 4,274,420;
4,777,954; 4,699,146; 4,458,696; 5,024,227; 4,243,051;
30 etc., which exemplify the continuing search for
conductive adhesive materials for use in medical
electrodes.

An objective of this invention, therefore, is to provide an electrode with an improved electroconductive skin-interface substrate, which will perform a similar function to, and eliminate the need for, an electrolyte solution, electrode paste or electrode gel.

Another objective of this invention is to provide an electrode with a skin-interface substrate having pressure sensitive adhesive properties which will enable the electrode to adhere to the skin without the use of tape or other securing mediums.

Another objective of this invention is to provide an adhesive substrate that has high tack so that minimal pressure is needed to apply it to the skin but is such that it can also be easily separable from the skin upon removal without any noticeable residue.

A further objective is to provide an electrode with a non-liquid skin-interface which is a film which will maintain a uniform thickness and will not separate to expose sections of a conductive support member to the skin.

An even further objective is to provide an electrode having a skin-interface substrate which will not decompose or dry out like electrodes utilizing electrolyte solutions under long periods of use.

Other objects and advantages of the instant invention will become apparent from a careful reading of the specification below.

SUMMARY OF THE INVENTION

The objectives of this invention are accomplished in a medical electrode, suitable for stimulation and monitoring applications, including an electrically conductive member capable of being connected to an external electro-medical apparatus. This conductive member may be a pliable sheet of material preferably having connected thereto a medium for securing positive electrical connection between the conductive member and the external electro-medical apparatus. Attached to the underside of the conductive member and extending away from the electrical connection is an electrically conductive skin-interface-substrate material, preferable in the form of a film. This material must have adhesive properties so that it will adhere to the skin of a patient. Preferably, this material also has plastic and hydrophilic properties. A suitable combination of the aforementioned adhesive, plastic and hydrophilic properties is provided by an adhesive composition which comprises an electrical conductive organic polymer plasticized with a polyhydric alcohol, e.g., glycerol.

Suitable electrically conductive organic polymers useful in the adhesive composition utilized in the medical electrode of the present invention include copolymers derived from the polymerization of acrylic acid and N-vinylpyrrolidone. Such copolymer may further include the following comonomers: acrylamide, 2-acrylamido propane sulfonic acid and methylene-bis-acrylamide.

The adhesive composition may also include a thickener such as a copolymer of ethylene and maleic anhydride, or methylvinylether and maleic anhydride, or N-vinylpyrrolidone and acrylic acid, or N-vinylpyrrolidone and vinylacetate.

The precursor to said adhesive composition is copolymerized to yield a film having suitable adhesive properties and electroconductivity properties for use as a medical electrode adhesive in the presence of an ultraviolet sensitive curing agent such as 2-hydroxy-2-methyl-1-phenyl-propan-2-one (available as Darocure 1173®), 4-(2-hydroxyethoxy)-phenyl-(2-hydroxy-2-phenyl-(2-hydroxy-2-propyl)ketone (available as Darocure 2959®), or 2,2-dimethoxy-2-phenylacetophenone (available as Irgacure® 651).

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will be more readily understood by reference to the drawings wherein like numerals refer to like elements and in which:

FIG. 1 shows a perspective view of the electrode;

and

FIG. 2 shows a cross-section in side elevation through the electrode of FIG. 1.

DETAILED DESCRIPTION OF THE INVENTION

Medical electrodes are intended for usage as efficient and effective transmission mediums between a patient's skin and an electro-medical apparatus. Primary to their operation is a uniform conductivity through the electrode itself and a uniform conductivity across the electrode skin-interface. Uniform conductivity through an electrode is most often interrupted by a non-uniformity in the electrode materials. Uniform conductivity across the electrode skin-interface is most often interrupted by a separation of some or all of the electrode interfacing material in contact with a patient's skin.

Preferably, the electrode is intended to be disposable. It is also intended to have adhesive properties sufficient to be self-adhering to a patient's skin for approximately 8-12 hours. However, it should contain sufficient flexibility and elasticity to move as a patient's skin moves while returning to original shape when permitted. Additionally, it is intended to provide uniform conductivity with even current densities of approximately 30 microamperes per square millimeter when subjected to a stimulus of about 60 milliamperes at 35 cycles per second having a pulse duration of about 250 microseconds. This electrode is intended to be easily handled, non-irritating to a patient's skin, and sterilizable.

The electrode configuration is shown in FIG. 1. A conductive member 11 is cut, stamped or otherwise shaped out of a piece of conductive material which may be aluminum foil or a polyester, e.g., a polyethylene

terephthalate (Mylar®) coated with aluminum or tin. The shape to which this conductive member 11 is formed will depend upon the particular application in which it is to be used. The shape is sometimes round but may be as shown in FIG. 1, rectangularly shaped.

Alternately, other metallic foils, conductive polymers, graphitized or metalized cloth or wire mesh may be used as the conductive member. In particular, the knit conductive fabric disclosed in U.S. Patent No. 4,722,354 may be utilized as the conductive member. For each material, an appropriate strength and thickness is to be chosen to yield a pliable, yet sufficiently strong member 11. When the conductive member 11 is of aluminum foil, it usually is of 1-10 mil thickness.

Secured to the outer surface of the conductive member 11 is a connector 13 for providing a medium to which external signal cables may be attached for electrically communicating with the conductive member 11. This connector 13 may be a conductive swaged snap fastener 13, as shown in the accompanying drawings, which is available commercially. This fastener 13 is mechanically and electrically attached to the conductive member 11, extending perpendicularly from the outer surface of this member 11. Alternatively, when the conductive member is a knit conductive fabric, the electrical connector may be stranded stainless steel as shown in U.S. Patent No. 4,722,359.

Abutting the inner surface of the conductive member 11 is an electrically conductive skin-interface substrate

15. This substrate 15 is a layer of material being typically a film or sheet which will be described below.

The conductive substrate 15 is shaped correspondingly to the conductive member 11. When constructed in combination with a rectangular member 11, the substrate 15 is also rectangular. The film thickness of this substrate 15 is uniform throughout, however, this uniform film may be of various thicknesses. A range of 20 to 100 mils, e.g., about 50 mils is common.

As will be discussed below, the substrate 15 is a film or sheet having adhesive properties, thus when it is brought into contact with the conductive member 11, it will adhere to that member 11 providing electrical connection with it.

A supporting scrim 17, Fig. 2 may be used in electrode configurations where a greater thickness substrate 15 film is used. This scrim 17, while not a necessary part of the electrode, will tend to support by being distributed throughout the substrate 15. A further advantage to the use of this scrim 17 is that it acts to reinforce and strengthen the substrate 15.

25

The scrim 17 is positioned midway through the thickness of the substrate 15, in alignment with the conductive member 11, and is of a size to extend completely under the conductive member 11. The scrim 17 can be a non-woven spun-bonded polyester fabric, a non-woven net of a stretched, embossed melt-extruded polymeric film, a non-woven sheet of polyolefin monofilaments heat-sealed together at their interstices

10

or a thin sheet of a thermoplastic polymer with holes heat-stamped in a geometric pattern.

In operation, the electrode is applied with the substrate 15 in direct contact with the skin. The adhesive properties of the substrate 15 eliminate the necessity for tape or other securing mediums to hold the electrode in continuous contact with the skin. The swaged fastener 13, or other suitable connector, receives electrical signals from an external apparatus. These signals are conducted into the conductive member 11 which in turn directly conducts them into the substrate 15. In this manner, current densities are uniformly distributed over the area of the substrate 15 in contact with the conductive member 11 and, in turn, are uniformly transmitted to the skin surface in contact with the substrate 15.

Primary to the unique structure of the electrode for eliminating the need for added electrode pastes, gels or electrolyte solutions, and for eliminating the need for securing mediums to hold the electrode in place, are the composition and structure of the substrate 15 material, enabling it to possess the desired physical, chemical and electrical properties.

Substrate 15 is a sheet or film of an electrically conductive organic polymer plasticized with a polyhydric alcohol, preferably glycerol.

30

The electrically conductive organic polymers that are utilized in preparing substrate 15 are derived from the copolymerization of a mixture of monomeric acrylic

acid and N-vinylpyrrolidone. Said organic polymer may comprise 25 to 75 parts per hundred, by weight (pph), e.g., 30 to 60 pph, acrylic acid and 2 to 30 pph, e.g. 10 to 30 pph, N-vinylpyrrolidone. In addition, the above
5 mixture of comonomers, the organic polymer, may further include additional comonomers; in particular, 1 to 20 pph, e.g., 1 to 8 pph, acrylamide is desirable.

Furthermore, the organic polymer may comprise, e.g.,
10 0.1 to 5 pph, e.g., about 2 pph, of a sulfonic acid-containing comonomer to (promote adhesion of the substrate), such as 2-acrylamide propane sulfonic acid (AMPS) and from, e.g., 0.1 to 5 pph, e.g., about 0.5 to
15 1.5 pph of a cross-linking agent, such as methylene-bis-acrylamide, to increase to molecular weight and cohesivity of the conductive organic polymer through crosslinking. Other comonomers having at least two copolymerizable olefinic moieties, especially difunctional derivatives of acrylic acids, may be
20 utilized in place of the preferred methylene bis-acrylamide). For example, polyethylene glycol dimethacrylates and diacrylates having a molecular weight of from about 200 to about 600 are suitable crosslinking agents.

25

In particular, it has been found that unexpectedly improved adhesion of the conductive organic polymer is obtained in an organic polymer, as described above, wherein the comonomer mixture includes both
30 methylene-bis-acrylamide and acrylamide, for example, from about 0.1 to 0.5 pph of methylene-bis-acrylamide and from about 1 to 8 pph of acrylamide provide a substrate having unexpectedly improved adhesion.

The comonomer mixture that is copolymerized to provide the conductive organic polymer will also include a polyhydric alcohol, e.g., polyhydroxyhydrocarbons and oxyalkyls, e.g., ethyleneglycol, diethyleneglycol, glycerol, etc. to plasticize the organic polymer. The polyhydric functions as a humectant, i.e., it absorbs moisture and promotes conductivity of the substrate 15. The polyhydric alcohol may comprise from 25 to 75 pph, preferably from 40 to 60 pph, e.g., about 37 to 53 pph of the comonomer mixture. Most preferably, the polyhydric alcohol is glycerol.

The comonomer mixture that is copolymerized to provide the conductive organic polymer may also include a thickening agent. The thickening agent may be a high molecular weight polymer or copolymer such as a N-vinylpyrrolidone/vinylacetate copolymer (Luviskol VA 73W or VA 64W) available from BASF; methylvinylether/maleic acid copolymer (Gantrez® S95), which is available from ISP; ethylene/maleic anhydride (EMA) Copolymer, which is available from Zeeland Chemical; and N-vinylpyrrolidone/acrylic acid Acrylidone® (ACP-1041 or Acrylidone 1005), which is available from ISP, and may comprise from about 0.5 to 8 pph of the comonomer mixture, e.g., about 2 to 5 pph. It has unexpectedly been found that N-vinylpyrrolidone/acrylic acid at a concentration of from 0.5 to 2.5, for example from 0.5 to 1.5 pph provides a substrate having improved adhesion. It has also been unexpectedly found that N-vinylpyrrolidone/vinylacetate provides adhesion similar to N-vinylpyrrolidone/acrylic acid.

The above comonomer mixture is preferably copolymerized or cured by thermal or ultraviolet (UV) radiation. Therefore, an ultraviolet sensitive curing agent is provided in the comonomer mixture at a concentration of from 0.05 to 3 pph, preferably from 0.5 to 2.0 pph. Suitable curing agents are 2-hydroxy-2-methyl-1-phenyl-propan-2-one (available as Darocur 1173®), 4-(2-hydroxyethoxy)phenyl (2-hydroxy-2-phenyl-(2-hydroxy-2-propyl)ketone (available as Darocure 2959™), or 2,2-dimethoxy-2-phenyl acetophenone (available as Irgacure® 651), all of which are available from Ciba-Geigy.

Thus, to prepare the substrate 15, the following gelled comonomer mixtures may be subjected to thermal or ultraviolet polymerization conditions:

	<u>Ingredient</u>	Broad	Preferred
		<u>Range pph</u>	<u>Range pph</u>
20	acrylic acid*	15 - 30	18 - 26
	N-vinylpyrrolidone	0.5 - 15	1 - 10
	acrylamide	0 - 10	0.5 - 2
	methylene-bis-acrylamide	0.01 - 2	0.03 - 0.1
	AMPS	0.1 - 6	2 - 5
25	thickener	0.5 - 8	0.5 - 3.0
	glycerin	25- 75	37 - 53
	UV sensitive curing agent	0.05 - 3	0.3 - 2.0
	distilled water	5 - 25	8 - 25

30 The acrylic acid is preferably partially neutralized with a basic potassium or sodium oxide, hydroxide, or carbonate. For example, from 33 to 67 molar percent acrylic acid may be neutralized.

The above conductive substrate has a capacity for absorbing and retaining large amounts of water. This property further promotes the conductivity of the copolymer.

As previously mentioned, while the above disclosed substrate will absorb large amounts of water, it is substantially insoluble in water because the conductive organic polymer contains at least 0.02 parts by weight per 100 parts of monomer of a crosslinking agent.

The substrate 15 compositions exhibit a tackiness which can be increased as the glycerol concentration is increased. As water and/or salt water is absorbed, the surface of the substrate material 15 softens. As a result, the substrate 15 will flow into pores and other irregularities in the skin, creating a mechanical interlock bond with the skin in addition to the already present adhesive bond. The bonding and, concomitantly, the electrical transmission of the electrode are enhanced as it "ages" in contact with the skin.

The flow condition eliminates air spaces between the skin and the substrate 15 to greatly reduce the impedance across the interface. This in turn greatly reduces the heat normally created at this interface. While the surface portion of the substrate 15 will flow, the greater portion of its mass will remain intact. Thus, the material resists separation or the development of irregular thicknesses. As a result, two heat and/or burn producing conditions, i.e., a high resistance across the interface due to an air layer which creates high

temperatures over the entire interface, and the physical contact of the conductive member 11 directly to the skin creating a shunt of the current to a small area and generating extreme temperature in that area, are avoided.

5

A secondary electrical effect is also improved as the electrode "ages." Present during the operation of all electrodes is a battery effect created at the skin interface due to the capacitance across this interface. 10 This battery effect causes some current to tend to circle backward towards its source of flow creating eddy currents. With this electrode of the invention, as water and body salts are absorbed into the electrode substrate, the interface area becomes more ionically (i.e., 15 electrically) homogenous, thus reducing the battery effect and any resulting eddy currents.

The electrode may be packaged for use in a sealed envelope of any of a number of suitable materials such as 20 polyethylene or aluminum foil. A release paper or film of the waxed or plastic-coated type can be used to protect the substrate 15 before application to a skin surface.

The invention is further illustrated by the following 25 examples which are illustrative of a specific mode of practicing the invention and is not intended as limiting the scope of the appended claims.

EXAMPLE I

30

The formulation designated as "A" in Table 1 is utilized to prepare the conductive substrate. This formulation is prepared as follows: Into a stainless

steel mixing container, equipped with a mechanical stirrer, is added 153.7 g of deionized water. With slow agitation, 45.8 g of potassium hydroxide is slowly added to water. After allowing the stirred caustic solution to cool to room temperature, 200.0 g of glacial acrylic acid, 17.4 g of acrylamide, 520.0 g of glycerin and 0.6 g of methylene-bis-acrylamide, in that order, are slowly added to the aqueous solution. The resulting mixture is stirred for an additional 15 minutes while the solution is purged with a slow stream of nitrogen gas to displace the residual dissolved oxygen gas from the solution. Finally, a mixture of 44.75 g of N-vinylpyrrolidone and 0.75 g of Irgacure® 651 is poured into the stirred aqueous solution. The resulting mixture is coated on and penetrates a polyester scrim, such as Reemay® 1006 or 2250 to provide a coating thickness of between 25 to 100, e.g., about 40 to 60 mils. Typical line speeds for the coating process vary from 15 to 50, e.g., 20 to 40 linear feet per minute. The coated polyester scrim is irradiated with ultraviolet radiation from a UV source, such as the electrodeless microwave energy activated curing system available as the 1-600-M from Fusion Systems Corporation operating at from 400 to 600 watts/inch. The cured composition is subject to testing for adhesivity (i.e., the bond between the scrim reinforced gel and a substrate, e.g., a standard stainless steel plate or possibly the mylar film web upon which the scrim reinforced gel is coated prior to being irradiated), using the Satec T1000 material Testing Machine (SATEC Systems, Grove City, Pennsylvania) equipped with an adjustable tilt table set for 90°. The test procedure for 90° peel strength required the pulling of a one-inch-wide strip of gel from the substrate (stainless steel plate or

Mylar® web) at 12 inches/minute and at an angle of 90° to the plane of the sample as per ASTM D1876, ASTM D3330M (American Society for Testing Materials, Philadelphia, Pennsylvania) or PSTC-1 and -3 (Pressure Sensitive Tape Council, Glenview, Illinois), and recording the average peel force in grams/one inch-width. (ASTM D3330M and PSTC-1 and -3 are for 180° peel testing but were adapted for use in this Example.) Formulations B through L are prepared similarly, except as specifically noted in Table 1.

The following results were obtained and reported in Table 1.

18
TABLE 1.

INGREDIENTS (WT-%)--FORMULATION#		A	B	C	D	E	F	F
ACRYLIC ACID ¹		20.000	19.910	19.910	19.910	18.810	18.601	18.601
5	POLYMER ADHESION/THICKENING AGENT	TYPE	0.000	0.000	0.000	² PAA	³ MVE/MA	MVE/MA
	AMOUNT	0.000	0.000	0.000	0.000	0.160	0.417	0.417
10	ACRYLAMIDE	1.740	1.730	1.730	1.730	1.650	1.648	1.648
	METHYLENE-BIS-ACRYLAMIDE	0.060	0.060	0.060	0.060	0.057	0.057	0.057
15	AMPS	2.000	1.990	1.990	2.000	1.890	1.895	1.895
	N-VINYLPYRROLIDONE	4.475	4.360	4.360	4.350	4.150	4.144	4.144
	IRGACURE-651	0.075	0.075	0.0701	0.070	0.095	0.0951	0.095
	GLYCERIN	52.000	51.770	51.760	51.760	49.30	49.258	49.258
20	DISTILLED WATER	15.370	15.650	15.650	15.650	20.860	20.849	20.849
	KOH (or NaOH)	4.580	4.4601	4.460	4.460	3.030	3.036	3.036
	UV SOURCE (WATTS)	600/400	600/400	600/400	600/400	600/400	600/400	400/400
	CONTACT TIME/LINE SPEED (FT/MIN)	14.000	14.000	14.000	14.000	14.000	14.000	35.000
25	THICKNESS (MILS)	45±5	53±5	90±7	73±17	80±12	70±13	32±6
	pH-VALUE - HYDROGEL	4.91	4.51		4.30	4.35	4.41	4.30
PEEL STRENGTH (G/1"-WIDTH)		483±60	639±58	919±114	925±97	619±144	894±72	470±35

19
TABLE 1. - cont.

INGREDIENTS (WT-%)/--FORMULATION		G	G	H	H	I	I
ACRYLIC ACID ¹		18.963	18.963	18.961	18.961	18.893	18.893
5	POLYMER ADHESION/THICKENING						
	AGENT	TYPE	MVE/MA	MVE/MA	MVE/MA	MVE/MA	MVE/MA
		AMOUNT	0.425	0.425	0.425	0.425	0.424
	ACRYLAMIDE		1.681	1.681	1.681	1.681	0.000
	METHYLENE BIS-ACRYLAMIDE		0.058	0.058	0.058	0.058	0.158
10	AMPS		0.000	0.000	0.000	0.000	1.925
	N-VINYLPYRROLIDONE		4.235	4.235	4.235	4.235	4.209
	IRGACURE-651		0.097	0.097	0.097	0.097	0.096
	GLYCERIN		50.216	50.216	50.211	50.211	50.034
	DISTILLED WATER		21.246	21.246	21.244	21.244	21.178
15	KOH (or NaOH)		3.090	3.090	3.089	3.089	3.084
	UV SOURCE (WATTS)		600/400	600/400	600/400	600/400	600/400
	CONTACT TIME/LINE SPEED (FT/MIN)		15.000	20.000	14.000	35.000	14.000
	THICKNESS (MILS)		56±6	66±5	76±23	47±12	75.8±7.4
20	pH-VALUE - HYDROGEL		4.62	4.70	4.61	4.55	4.48
	PEEL STRENGTH G/V -WIDTH)		669±91	722±130	754±290	217±21	149.6±38.6
							13.7±24.2

TABLE 1 - cont.

INGREDIENTS (WT.%)--FORMULATION	J	J	K	K	L	L
ACRYLIC ACID ¹	18.928	18.928	19.184	19.184	18.898	18.898
POLYMER ADHESION/THICKENING AGENT						
	TYPE	MVE/MA	MVE/MA	MVE/MA	MVE/MA	MVE/MA
	AMOUNT	0.425	0.425	0.433	0.4331	0.424
ACRYLAMIDE		1.743	1.743	0.000	0.000	0.000
METHYLENE-BIS-ACRYLAMIDE		0.158	0.158	0.158	0.059	0.058
AMPS		0.000	0.000	0.000	0.000	2.000
N-VINYLPYRROLIDONE		4.217	4.217	4.296	4.2961	4.210
IRGACURE-651		0.096	0.096	0.098	0.0981	0.096
GLYCERIN --		50.126	50.126	51.068	51.068	50.046
DISTILLED WATER		21.217	21.217	21.615	21.615	21.183
KOH (or NaOH)		3.090	3.090	3.148	3.148	3.085
UV SOURCE (WATTS)		600/400	400/400	600/400	400/400	600/400
CONTACT TIME/LINE SPEED (FT/MIN)		14.000	35.000	14.000	35.000	14.000
THICKNESS (MILS)		97.2±15.1	66.4±5.4	60±11	43±6	66±14
pH-VALUE - HYDROGEL		4.61	4.56	4.51	4.53	4.41
PEEL STRENGTH (G/I"-WIDTH)		80.2±36.6	37.4±10.5	314±85	226±32	436±72

¹The acrylic acid is partially neutralized.

As shown in Table 1, increasing the line speed from 14 to 35 linear feet per min, as shown for Formulations, F, H, I, J, K and L, resulted in a decrease in coating thickness and also a decrease in adhesivity. (Note that increasing the line speed from 15 to 20 linear feet per minute also had the same result, although the difference was diminished in this instance. See Formulation G.) Also, while not shown, Formulations similar to those shown in Table 1, wherein the crosslinking agent, methylene bis-acrylamide were absent, showed effectively no adhesivity, while Formulations I and J, wherein the crosslinking agent concentration was at 0.15 as compared to Formulations F, H, K and L wherein the crosslinking agent concentration was about .06 pph showed inferior adhesivity.

Nevertheless, the results in Table 1 clearly show unexpectedly improved adhesivity, wherein the gel mixture comprises up to 3 pph, e.g., from about 0.5 to 2 pph, acrylamide, and from about 0.03 to about 0.1, e.g., about 0.06 pph, methylene bis-acrylamide.

EXAMPLE II

This Example is carried out as discussed above for Example I, except that the formulations tested differ, as described in Table 2 below.

22

TABLE 2.

INGREDIENTS (WT-%)---FORMULATION#	M	M	M	M	N	O	P
ACRYLIC ACID	20.000	20.000	20.000	20.000	20.000	20.000	20.000
POLYMER ADHESION/THICKENING AGENT							
TYPE	NVP/AA	NVP/AA	NVP/AA	NVP/AA	z MVE/MA	EMA	NVP/AA
AMOUNT	1.000	1.000	1.000	1.000	1.000	1.000	1.000
AMPS	4.000	4.000	4.000	4.000	2.000	2.000	2.000
N-VINYLPYRROLIDONE	4.000	4.000	4.000	4.000	4.000	4.000	4.000
IRGACURE-2959	0.200	0.200	0.200	0.200	0.200	0.200	0.200
DAROCURE-1173	0.200	0.200	0.200	0.200	0.200	0.200	0.200
GLYCERIN	40.000	40.000	40.000	40.000	45.000	45.000	45.000
DISTILLED WATER	24.500	24.500	24.500	24.500	21.500	21.500	21.500
NaOH	6.000	6.000	6.000	6.000	6.000	6.000	6.000
HIGHLINK-AA4	0.100	0.100	0.100	0.100	0.100	0.100	0.100
TOTAL	100.000	100.000	100.000	100.000	100.000	100.000	100.000
THICKNESS (MILS)	48.4	52.4	49.1	50.3	46.6	32.0	34.8
IMPEDANCE (OHM-CM)					2604	5258	3350
PEEL STRENGTH RATIO: MYLAR-PE	0.7	1.3	1.3	2.0	0.2	0.7	0.5
90° PEEL STRENGTH (G/1"-WIDTH) - T.L.	619	479	438	338	296	146	593
90° PEEL STRENGTH (G/1%WIDTH) - B.L.	404	607	588		723	105	274

23

TABLE 2. - cont.

INGREDIENTS (WT-%)-/-.FORMULATION#	Q	R	S	T	U	V	W	X
ACRYLIC ACID	20.000	20.000	20.000	20.000	20.000	20.000	20.000	20.000
POLYMER ADHESION/THICKENING AGENT								
TYPE	NVP/AA	NVP/AA	NVP/AA	NVP/AA	EMA	EMA	EMA	EMA
AMOUNT	1.000	1.000	1.000	1.000	1.000 ¹	1.000	1.000	1.000
AMPS	2.000	4.000	2.000	4.000	2.000	4.000	2.000	2.000
N-VINYLPYRROLIDONE	4.000	4.000	8.000	4.000	4.000	4.000	8.000	4.000
IRGACURE-2959	0.200	0.200	0.200	0.200	0.200	0.200	0.200	0.200
DAROCURE-1173	0.200	0.200	0.200	0.200	0.200	0.200	0.200	0.200
GLYCERIN	40.000	40.000	40.000	40.000	40.000	40.000	40.000	40.000
DISTILLED WATER	26.500	24.500	22.500	24.500	26.500	24.500	22.500	20.500
NaOH	6.000	6.000	6.000	6.000	6.000	6.000	6.000	6.000
HIGHLINK-AA ⁴	0.100	0.100	0.100	0.100	0.100	0.100	0.100	0.100
TOTAL	100.00	100.0	100.0	100.0	100.0	100.0	100.0	100.0
THICKNESS (MILS)	45.1	46.3	40.4	37.1	50.5	48.1	38.2	38.9
IMPEDANCE (OHM-CM)	2132	1146	1559	2427	3726	4202	2801	2110
PEEL STRENGTH RATIO: MYLAR:PE	2.4	2.6	3.7	3.6	0.8	0.9	0.9	0.8
90- PEEL STRENGTH (G/1"WIDTH), T.L.	177	209	170	117	137	90.3	92.1	1.5
90- PEEL STRENGTH (G/1"WIDTH B.L.	423	538	630	424	115	83.0	79.4	89.4

¹N-vinylpyrrolidone/acrylic acid copolymer (Acrylidone® ACP-1041).²Gantrez® 595.³Ethylene Maleic anhydride copolymer (available from Zeeland Chemical)⁴Diacrylamidoacetic acid (available from Hoechst Celanese)

TABLE 2. - cont.

INGREDIENTS (WT-%)-/.-FORMULATION#	Y	Z	AA	AB	AC
ACRYLIC ACID	20.000	20.000	20.000	20.000	20.000
POLYMER ADHESION/THICKENING AGENT					
	TYPE	NONE ¹ NVP/AA	² NVP/AA	³ VP/VA70:30	⁴ VP/VA 60:40
	AMOUNT	0	2.75	2.75	2.75
AMPS		4.000	4.000	4.000	4.000
N-VINYLPYRROLIDONE		4.000	4.000	4.000	4.000
IRGACURE-2959		0.200	0.200	0.200	0.200
DAROCURE-1173		0.200	0.200	0.200	0.200
GLYCERIN		40.000	40.000	40.000	40.000
DISTILLED WATER		22.750	22.750	22.750	22.750
NaOH		6.000	6.000	6.000	6.000
HIGHLINK-AA		0.100	0.100	0.100	0.100
TOTAL		97.25	100.0	100.0	100.0
THICKNESS (MILS)		49	44	54	46
IMPEDANCE (OHM-CM)		2419	2576	2710	2284
PEEL STRENGTH RATIO: MYLAR:PE		1.7	1.1	1.6	1.7
90° PEEL STRENGTH (G/1"-width)TL		622	720	1087	917
90° PEEL STRENGTH (G/1"WIDTH), T.L		362	664	689	530

¹N-vinylpyrrolidone/acrylic acid copolymer 250,000 MW(Acrylidone 1005)²N-vinylpyrrolidone/vinyl acetate 70:30 ratio (Luviskol VA73W from BASF)³N-vinylpyrrolidone/vinyl acetate 60:40 ratio (Luviskol VA64W from BASF)

The process of preparing the samples of this Example, the scrim is drawn through a trough of feedmix or monomer syrup and out through an aperture and under a doctor blade or gate adjusted to vary the thickness of the coating onto a 5-mil Mylar® polyester web, which immediately passes at a line speed of 20 linear feet per minute under the first of two 600 watts/in UV lamp irradiators. The web moves to a take-up station and a 2.5-mil polyethylene film is attached prior to rolling up the hydrogel sheet on a 6" core.

The peel strength or adhesivity of the cured hydrogel on the Mylar® side and on the polyethylene side is measured off of a stainless steel plate. The significance of the two peel strength values are important as they are measures of how well the hydrogel sheet will bond to the conductive or metallic dispersive element (the polyethylene film side) and to the patient (the Mylar® film side). Other factors being equal, the ratio of these two peel strengths also relates to the ratio of the gel thicknesses on each side of the scrim. Generally, it is preferred to have the peel strength on the Mylar® film side to be higher than the peel strength on the polyethylene film side.

25

The volume resistivity or bulk impedance is measured using a Hewlett Packard Model 4800A Vector Impedance Meter. Circles, which are 1.128 inches in diameter or 1-inch square in surface area and known thicknesses, are cut from the hydrogel sheet. The circle is placed between two stainless steel polished plates having 1-inch square surface area. Each plate is connected to the input leads of the meter and the impedance determined at a frequency

of 1,000 Hz. The impedance in ohms is multiplied by the surface area in squared centimeters of the gel and divided by the thickness of the gel in centimeters. The volume resistivity is reported as ohm-cm.

5

It is clear from the results reported that the N-vinylpyrrolidone acrylic acid copolymer provides improved adhesion as compared to the other thickeners when compared at equal concentrations of N-vinylpyrrolidone monomer, AMPS and glycerine concentration. In particular compare Formulations Q and U, R and V, S and W, T and X, and P, O and N.

15 In addition, the N-vinylpyrrolidone/vinylacetate copolymer thickener is substantially equivalent to N-vinylpyrrolidone/acrylic acid thickener in improving the adhesion of the conductive layer. Compare Formulations AB and AC with Formulations Z and AA. Also, the peel strength ratio of the N-vinylpyrrolidone thickener-
20 containing conductive polymer is equal or better than the peel strength ratio of the N-vinylpyrrolidone/acrylic acid thickener-containing conductive polymer.

25 While particular embodiments of the invention have been described, it will be understood, of course, that the invention is not limited thereto since many obvious modifications can be made and it is intended to include within this invention any such modifications as will fall within the scope of the appended claims. For example, it
30 will be appreciated, by those skilled in the art, that other carboxylic substituted vinyl or propenyl monomers may be substituted for acrylic acid, e.g., methacrylic acid, crotonic acid, isocrotonic acid, itaconic acid,

maleic acid, fumaric acid or their half ester/acid derivatives.

Other alkaline materials can be utilized to
5 neutralize the acrylic acid monomer, e.g., mono and poly
positive alkaline materials, e.g., sodium, potassium,
calcium, magnesium, aluminum basic oxides, hydroxides or
carbonates may be used as well as ammonium hydroxide,
etc.

10

Other copolymerizable N-vinyl lactam monomers may be
substituted for N-vinylpyrrolidone, e.g., N-vinyl-
ε-caprolactam or N-vinylbutyrolactam.

15

Other plasticizers and/or humectants may be
substituted for glycerol including urea and the
polyhydroxyorganics described above.

Other thickeners or viscosity increasing agents
20 which may be used in the medical electrodes of the
present invention include polyacrylamide, polyvinyl
alcohol, polyacrylic acid, polyethylene oxide, methyl
cellulose, ethyl cellulose, carboxymethyl cellulose,
hydroxyethyl cellulose and polyacrylamidealkylsulfonic
25 acid.

Finally, the conductive polymer may include
particulate reinforcing agents and/or fillers, such as
silica, e.g. Cabosil®.

WHAT IS CLAIMED:

1 An electrode providing electrical contact with a patient's skin comprising:

5 a conductive member including means for connection to an external electrical apparatus; and means for electrically interfacing to said patient's skin being electrically and mechanically connected to said conductive member, said interfacing means being a non-liquid film and which comprises an
10 electrically conductive organic polymer plasticized with a polyhydric alcohol with said organic polymer being derived from a monomeric mixture comprising from about 15 to 30 pph acrylic acid, 0.5 to 30 pph N-vinylpyrrolidone and 0.01 to 2 pph of a crosslinking agent and from about
15 0.5 to 8 pph of a thickening agent selected from the group consisting of N-vinylpyrrolidone/acrylic acid copolymers and N-vinylpyrrolidone/vinylacetate copolymers.

20

2. The electrode of claim 1 wherein said polyhydric alcohol is glycerol.

3. The electrode of claim 2 wherein said
25 crosslinking agent is selected from the group consisting of methylene bis-acrylamide and polyethylene glycol acrylates and diacrylates having a molecular weight from about 200 to about 600.

30 4. The electrode of claim 3 wherein said monomeric mixture further comprises from about 0.1 to 6 pph of a sulfonic acid-containing comonomer.

5. The electrode of claim 3 wherein said monomeric mixture further comprising from about 0.5 to 2 pph acrylamide.

5 6. The electrode of claim 5 comprising from 0.5 to 2 pph of acrylamide and from 0.03 to 0.1 pph methylene bis-acrylamide.

7. The electrode of claim 5 wherein said monomeric
10 mixture further comprises from about 40 to 60 pph of glycerol.

8. The electrode of claim 7 wherein said
sulfonic-acid-containing comonomer is 2-acrylamido
15 propane sulfonic acid.

9. The electrode of claim 1 wherein said monomeric mixture further comprises from 0.05 to 3 pph of an ultraviolet sensitive curing agent.

20

10. The electrode of claim 9 wherein said ultraviolet sensitive curing agent is selected from the group consisting of 2-hydroxy-2-methyl-1-phenyl-propan-2-one 4-(2-hydroxyethoxy)phenyl (2-hydroxy-2-phenyl-2-hydroxy-2-propyl)ketone or 2,2-dimethoxy-2-phenyl-acetophenone and mixtures thereof.

11. An electrode providing electrical contact with a patient's skin comprising:

30 a conductive member including means for connection to an external electrical apparatus; and means for electrically interfacing to said patient's skin being electrically and mechanically

30

connected to said conductive member, said interfacing means being a non-liquid film which is easily separable from the skin upon removal without any noticeable residue and which consists essentially of an electrically
5 conductive organic polymer plasticized with a polyhydric alcohol with said organic polymer being derived from a monomeric mixture comprising from about 15 to 30 pph acrylic acid, 0.5 to 15 pph N-vinylpyrrolidone, 0.5 to 2 pph acrylamide and 0.03 to 0.1 pph methylene
10 bis-acrylamide.

12. The electrode of claim 11 wherein said monomeric mixture is admixed with from about 0.5 to 8 pph of a thickening agent.

15

13. The electrode of claim 12 wherein said polyhydric alcohol is glycerol.

14. The electrode of claim 13 wherein said monomeric
20 mixture further comprises from about 0.1 to 5 pph of a sulfonic-acid-containing comonomer.

15. The electrode of claim 14 wherein said sulfonic acid-containing comonomer is 2-acrylamide propane
25 sulfonic acid.

16. The electrode of claim 13 wherein said monomeric mixture further comprises from 0.05 to 3 pph of an ultraviolet sensitive curing agent.

30

17. The electrode of claim 16 wherein said ultraviolet sensitive curing agent is selected from the group consisting of 2-hydroxy-2-methyl-

1-phenyl-propan-2-one 4-(2-hydroxyethoxy)phenyl
(2-hydroxy-2-phenyl- (2-hydroxy-2-propyl) ketone or
2,2-dimethoxy-2phenyl-acetophenone and mixtures therefor.

5 18. The electrode of claim 16 wherein said
monomeric mixture comprises from 40 to 60 pph glycerol.

19. The electrode of claim 1 wherein said monomeric
mixture comprises from about 2 to 5 pph of a thickening
10 agent comprising a N-vinylpyrrolidone/acrylic acid
copolymer.

20. The electrode of claim 1 wherein said monomeric
mixture comprises from about 0.5 to 2.5 pph of a
15 thickening agent comprising a N-vinylpyrrolidone/acrylic
acid copolymer.

21. The electrode of claim 1 wherein said mixture
comprises from about 0.5 to 1.5 pph of a thickening agent
20 comprising a N-vinylpyrrolidone/acrylic acid copolymer.

22. The electrode of claim 1 wherein said N-
vinylpyrrolidone/acrylic acid copolymer is Acrylidone®
ACP-1041.

25

23. The electrode of claim 1 wherein said monomeric
mixture comprises from about 0.5 to 2.5 pph of a
thickening agent comprising a N-
vinylpyrrolidone/vinylacetate copolymer.

30

24. The electrode of claim 23 wherein said copolymer comprises from about 50 to 80 pph N-vinylpyrrolidone and from about 50 to 20 pph vinylacetate.

5

25. The electrode of claim 1 wherein said N-pyrrolidone/acrylic acid copolymer is Acrylidone® 1005.

FIG. 1.





FIG. 2.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/02620

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61B 5/0408; A61N 1/04

US CL : 252/500; 600/391, 395; 607/149, 152

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 251/500; 600/391, 395; 606/32; 607/149, 152

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4,391,278 A (CAHALAN et al) 05 July 1983, entire document.	1-25
A	US 4,848,353 A (ENGEL) 18 July 1989, entire document.	1-25



Further documents are listed in the continuation of Box C.



See patent family annex.*

* "A"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"I."	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

14 APRIL 1999

Date of mailing of the international search report

04 MAY 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

LEE S. COHEN

Telephone No. (703) 308-2998